Valuation: ICAD

Market Cap 11Cr 9.15Cr 8.57Cr 7.82Cr 15Cr 1.01TCr 15Cr 100.82Cr 39Cr 504.29Cr 40Cr 39Cr 1.68TCr P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 8.87Cr 7.69Cr 7.2Cr 6.57Cr 12Cr 846.48Cr 13Cr 85Cr 33Cr 423.84Cr 33Cr 33Cr 1.41TCr EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
12.73
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 10/03/2023
Director of Finance/CFO 54 17/07/2025
Corporate Secretary - 17/07/2025
Date Insider Type Main position Quantity % Market Cap.
17/07/25 Issuer sale

Director

15,53,657 5.8540%
17/07/25 Issuer sale

Chief Financial Officer

1,58,488 0.5972%
17/07/25 Issuer sale

Chief Technology Officer

3,51,145 1.3231%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%-.--%+51.17% 11Cr
+0.45%+4.44%+26.41%+11.69% 22TCr
-1.24%+3.73%+0.67%-19.47% 15TCr
+0.07%+6.88%-16.14%+31.45% 14TCr
+0.43%+8.26%-49.64%+0.69% 7.42TCr
-0.66%+4.89%+21.31%+15.89% 5.4TCr
-1.41%-0.54%-15.65%-17.15% 5.09TCr
-0.34%+5.17%+26.49%+17.17% 4.22TCr
+0.22%+3.57%+45.10%+43.66% 4.07TCr
-0.69%+3.26%-2.53%+1.02% 3.29TCr
Average +0.10%+4.77%+3.60%+13.61% 8.06TCr
Weighted average by Cap. -0.19%+6.23%+4.05%+8.45%

Financials

2023 2024
Net sales 1.73Cr 1.5Cr 1.41Cr 1.28Cr 2.41Cr 165.18Cr 2.45Cr 17Cr 6.46Cr 83Cr 6.5Cr 6.36Cr 275.78Cr 1.96Cr 1.7Cr 1.59Cr 1.45Cr 2.73Cr 187.02Cr 2.77Cr 19Cr 7.32Cr 94Cr 7.36Cr 7.2Cr 312.25Cr
Net income -48.47L -41.99L -39.35L -35.89L -67.47L -46Cr -68.51L -4.63Cr -1.81Cr -23Cr -1.82Cr -1.78Cr -77Cr -56.16L -48.66L -45.59L -41.58L -78.18L -54Cr -79.38L -5.36Cr -2.1Cr -27Cr -2.11Cr -2.06Cr -89Cr
Net Debt -2.12Cr -1.84Cr -1.72Cr -1.57Cr -2.95Cr -202.29Cr -3Cr -20Cr -7.92Cr -101.29Cr -7.96Cr -7.79Cr -337.74Cr -1.68Cr -1.46Cr -1.37Cr -1.25Cr -2.34Cr -160.66Cr -2.38Cr -16Cr -6.29Cr -80Cr -6.32Cr -6.19Cr -268.23Cr
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock